Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Gilead Sciences, Inc. v. Merck & Co., Inc.
Case Number:
16-2302
Court:
Nature of Suit:
830 Patent Infringement (Fed. Question)
Companies
Sectors & Industries:
-
July 06, 2018
Fed. Circ. OKs $14M For Gilead After Merck's Patent Lies
The Federal Circuit on Friday summarily affirmed a California federal judge's decision to make Merck pay Gilead Sciences Inc. $14 million in attorneys' fees after it was uncovered that a Merck in-house attorney behaved so outrageously during patent prosecution that the court had to overturn a $200 million infringement verdict.
-
April 25, 2018
Fed. Circ. Says Merck Atty's Lies Doomed $200M Patent Win
The Federal Circuit upheld a decision wiping out a $200 million patent verdict Merck won against Gilead concerning hepatitis C drugs, agreeing Wednesday that "dishonest and duplicitous" behavior by a Merck in-house attorney barred the drugmaker from asserting the patents.